Cargando…
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
Liquid biopsy analytes such as cell-free DNA (cfDNA) and circulating tumor cells (CTCs) exhibit great potential for personalized treatment. Since cfDNA and CTCs are considered to give additive information and blood specimens are limited, isolation of cfDNA and CTC in an “all from one tube” format is...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406821/ https://www.ncbi.nlm.nih.gov/pubmed/30781720 http://dx.doi.org/10.3390/cancers11020238 |
_version_ | 1783401412203380736 |
---|---|
author | Keup, Corinna Storbeck, Markus Hauch, Siegfried Hahn, Peter Sprenger-Haussels, Markus Tewes, Mitra Mach, Pawel Hoffmann, Oliver Kimmig, Rainer Kasimir-Bauer, Sabine |
author_facet | Keup, Corinna Storbeck, Markus Hauch, Siegfried Hahn, Peter Sprenger-Haussels, Markus Tewes, Mitra Mach, Pawel Hoffmann, Oliver Kimmig, Rainer Kasimir-Bauer, Sabine |
author_sort | Keup, Corinna |
collection | PubMed |
description | Liquid biopsy analytes such as cell-free DNA (cfDNA) and circulating tumor cells (CTCs) exhibit great potential for personalized treatment. Since cfDNA and CTCs are considered to give additive information and blood specimens are limited, isolation of cfDNA and CTC in an “all from one tube” format is desired. We investigated whether cfDNA variant sequencing from CTC-depleted blood (CTC-depl. B; obtained after positive immunomagnetic isolation of CTCs (AdnaTest EMT-2/Stem Cell Select, QIAGEN)) impacts the results compared to cfDNA variant sequencing from matched whole blood (WB). Cell-free DNA was isolated using matched WB and CTC-depl. B from 17 hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer patients (QIAamp MinElute ccfDNA Kit, QIAGEN). Cell-free DNA libraries were constructed (customized QIAseq Targeted DNA Panel for Illumina, QIAGEN) with integrated unique molecular indices. Sequencing (on the NextSeq 550 platform, Illumina) and data analysis (Ingenuity Variant Analysis) were performed. RNA expression in CTCs was analyzed by multimarker quantitative PCR. Cell-free DNA concentration and size distribution in the matched plasma samples were not significantly different. Seventy percent of all variants were identical in matched WB and CTC-depl. B, but 115/125 variants were exclusively found in WB/CTC-depl. B. The number of detected variants per patient and the number of exclusively detected variants per patient in only one cfDNA source did not differ between the two matched cfDNA sources. Even the characteristics of the exclusively detected cfDNA variants in either WB or CTC-depl. B were comparable. Thus, cfDNA variants from matched WB and CTC-depl. B exhibited no relevant differences, and parallel isolation of cfDNA and CTCs from only 10 mL of blood in an “all from one tube” format was feasible. Matched cfDNA mutational and CTC transcriptional analyses might empower a comprehensive liquid biopsy analysis to enhance the identification of actionable targets for individual therapy strategies. |
format | Online Article Text |
id | pubmed-6406821 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64068212019-03-21 Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer Keup, Corinna Storbeck, Markus Hauch, Siegfried Hahn, Peter Sprenger-Haussels, Markus Tewes, Mitra Mach, Pawel Hoffmann, Oliver Kimmig, Rainer Kasimir-Bauer, Sabine Cancers (Basel) Article Liquid biopsy analytes such as cell-free DNA (cfDNA) and circulating tumor cells (CTCs) exhibit great potential for personalized treatment. Since cfDNA and CTCs are considered to give additive information and blood specimens are limited, isolation of cfDNA and CTC in an “all from one tube” format is desired. We investigated whether cfDNA variant sequencing from CTC-depleted blood (CTC-depl. B; obtained after positive immunomagnetic isolation of CTCs (AdnaTest EMT-2/Stem Cell Select, QIAGEN)) impacts the results compared to cfDNA variant sequencing from matched whole blood (WB). Cell-free DNA was isolated using matched WB and CTC-depl. B from 17 hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer patients (QIAamp MinElute ccfDNA Kit, QIAGEN). Cell-free DNA libraries were constructed (customized QIAseq Targeted DNA Panel for Illumina, QIAGEN) with integrated unique molecular indices. Sequencing (on the NextSeq 550 platform, Illumina) and data analysis (Ingenuity Variant Analysis) were performed. RNA expression in CTCs was analyzed by multimarker quantitative PCR. Cell-free DNA concentration and size distribution in the matched plasma samples were not significantly different. Seventy percent of all variants were identical in matched WB and CTC-depl. B, but 115/125 variants were exclusively found in WB/CTC-depl. B. The number of detected variants per patient and the number of exclusively detected variants per patient in only one cfDNA source did not differ between the two matched cfDNA sources. Even the characteristics of the exclusively detected cfDNA variants in either WB or CTC-depl. B were comparable. Thus, cfDNA variants from matched WB and CTC-depl. B exhibited no relevant differences, and parallel isolation of cfDNA and CTCs from only 10 mL of blood in an “all from one tube” format was feasible. Matched cfDNA mutational and CTC transcriptional analyses might empower a comprehensive liquid biopsy analysis to enhance the identification of actionable targets for individual therapy strategies. MDPI 2019-02-18 /pmc/articles/PMC6406821/ /pubmed/30781720 http://dx.doi.org/10.3390/cancers11020238 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Keup, Corinna Storbeck, Markus Hauch, Siegfried Hahn, Peter Sprenger-Haussels, Markus Tewes, Mitra Mach, Pawel Hoffmann, Oliver Kimmig, Rainer Kasimir-Bauer, Sabine Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer |
title | Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer |
title_full | Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer |
title_fullStr | Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer |
title_full_unstemmed | Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer |
title_short | Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer |
title_sort | cell-free dna variant sequencing using ctc-depleted blood for comprehensive liquid biopsy testing in metastatic breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406821/ https://www.ncbi.nlm.nih.gov/pubmed/30781720 http://dx.doi.org/10.3390/cancers11020238 |
work_keys_str_mv | AT keupcorinna cellfreednavariantsequencingusingctcdepletedbloodforcomprehensiveliquidbiopsytestinginmetastaticbreastcancer AT storbeckmarkus cellfreednavariantsequencingusingctcdepletedbloodforcomprehensiveliquidbiopsytestinginmetastaticbreastcancer AT hauchsiegfried cellfreednavariantsequencingusingctcdepletedbloodforcomprehensiveliquidbiopsytestinginmetastaticbreastcancer AT hahnpeter cellfreednavariantsequencingusingctcdepletedbloodforcomprehensiveliquidbiopsytestinginmetastaticbreastcancer AT sprengerhausselsmarkus cellfreednavariantsequencingusingctcdepletedbloodforcomprehensiveliquidbiopsytestinginmetastaticbreastcancer AT tewesmitra cellfreednavariantsequencingusingctcdepletedbloodforcomprehensiveliquidbiopsytestinginmetastaticbreastcancer AT machpawel cellfreednavariantsequencingusingctcdepletedbloodforcomprehensiveliquidbiopsytestinginmetastaticbreastcancer AT hoffmannoliver cellfreednavariantsequencingusingctcdepletedbloodforcomprehensiveliquidbiopsytestinginmetastaticbreastcancer AT kimmigrainer cellfreednavariantsequencingusingctcdepletedbloodforcomprehensiveliquidbiopsytestinginmetastaticbreastcancer AT kasimirbauersabine cellfreednavariantsequencingusingctcdepletedbloodforcomprehensiveliquidbiopsytestinginmetastaticbreastcancer |